Cancer and Molecular Therapies

Dr. Michael Milyavsky

Dr. Milyavsky is at the Department of Pathology, School of Medicine, where he is a principal investigator and the head of the Hematopoietic Stem Cell and Leukemia Laboratory. Dr. Milyavsky is a graduate of the Weizmann Institute of Science, having completed his M.Sc. and Ph.D. in molecular and cellular biology. Michael completed his post-doctoral training in hematopoiesis and leukemia at the University of Toronto, Canada.

www.milyavskylab.com

Leukemia

hematopoietic stem cells

As we age, our blood (hematopoietic ) stem cells (HSCs) suffer from accumulated mutations in their DNA that eventually can lead to accelerated leukemogenesis and/or inefficient immune response . How normal and leukemia stem cells regenerate after acute or chronic damage is our main research interest. Dr. Milyavsky addresses these questions by studying DNA damage signaling and its outcomes in highly purified human normal and leukemia cell subsets . Uniquely, we use humanized mice and genetic engineering to monitor in real time how normal and leukemia stem cells communicate with other bone marrow cells in the process of regeneration . We will use this new understanding to stop regeneration of leukemia cells without harming normal HSC?